Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium–hydrogen exchanger 3 (NHE3) is a membrane transporter encoded by the SLC9A3 gene. It is primarily expressed on the apical surface of epithelial cells in the renal proximal tubule and small intestine. NHE3 mediates electroneutral exchange of extracellular sodium ions for intracellular hydrogen ions with a stoichiometry of 1:1. This process is essential for bulk reabsorption of filtered sodium in the kidney and for nutrient-independent sodium uptake in the gut. By regulating these exchanges, NHE3 plays a critical role in maintaining systemic fluid volume, blood pressure, acid-base balance, and overall electrolyte homeostasis. Its activity is tightly regulated by various kinases and interacting proteins; dysregulation or inhibition can lead to significant physiological effects relevant to hypertension management or treatment of constipation-predominant irritable bowel syndrome through drugs like tenapanor[1][2][4].
Inhibition of sodium reabsorption by blocking the Na+/H+ exchange activity in the intestine and kidney
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium–hydrogen exchanger 3 (NHE3).